Chrysalis Biotherapeutics has filed a notice of an exempt offering of securities to raise $3 Million in New Equity and Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, Chrysalis Biotherapeutics is raising up to $3,000,000.00 in new funding. Sources indicate that as part of senior management President, Darrell Carney played a key role…